ArticleInternational journal of cancer2021

Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.

Nizar M Tannir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.